NPY Y5 Receptor Subtype

Pharmacological Characterization with Antisense Oligodeoxynucleotide Screening Strategy
  • Andrea O. Schaffhauser
  • Alain Stricker-Krongrad
  • Karl G. Hofbauer
Part of the Methods in Molecular Biology™ book series (MIMB, volume 153)


Neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) are endogenous 36-amino acid peptides belonging to the same family. Different receptor subtypes have been identified in the NPY/PYY/PP family (1), and mammalian subtypes are now classified collectively as NPY receptors, several of which (namely Y1, Y2, Y4, Y5, and Y6) have been cloned (2, 3, 4, 5, 6, 7, 8, 9, 10). Based on studies using full-length peptides, C- or N-terminal fragments, and modified peptides of the NPY/PYY/PP family (11,12), the NPY Y5 receptor subtype was proposed as a mediator of NPY-induced feeding. At the time when the NPY Y5 receptor was cloned, neither NPY Y5 antagonists nor NPY Y5 knockout mice were available. Therefore we used an antisense oligodeoxynucleotide (antisense ODN) strategy to assess the proposed role of the NPY Y5 receptor subtype in the regulation of feeding.


Guide Cannula Radioligand Binding Assay Antisense Sequence Antisense ODNs Antisense Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Blomqvist A. G. and Herzog H. (1997) Y-receptor subtypes: how many more? Trends Neurosci. 20, 294–298.PubMedCrossRefGoogle Scholar
  2. 2.
    Bard J. A., Walker M. W., Branchek T. A., and Weinshank R. L. (1995) Cloning and functional expression of a human Y4 subtype for pancreatic polypeptide, neuropeptide Y and peptide YY. J. Biol. Chem. 270, 26,762–26,765.PubMedCrossRefGoogle Scholar
  3. 3.
    Gehlert D. R., Beavers L. S., Johnson D., Gackenheimer S. L., Schober D. A. and Gadski R. A. (1996) Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol. Pharmacol. 49, 224–228.PubMedGoogle Scholar
  4. 4.
    Gerald C., Walker M. W., Vaysse P. J., Branchek T. A., and Weinshank R. L. (1995) Expression cloning and pharmacological characterization of a human hip-pocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem. 270, 26,758–26,761.PubMedCrossRefGoogle Scholar
  5. 5.
    Gerald C., Walker M. W., Criscione L., Gustafson E. L., Batzl Hartmann C., Smith K. E., et al. (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382, 168–171.PubMedCrossRefGoogle Scholar
  6. 6.
    Gregor P., M. L. Millham, Y. Feng, L. B. DeCarr, M. L. McCaleb and L. J. Cornfield (1996) Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family. FEBS Lett. 381, 58–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Larhammar D., Blomqvist A. G., Yee F., Jazin E., Yoo H., and Wahlestedt C. (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type.J. Biol. Chem. 267, 10,935–10,938.PubMedGoogle Scholar
  8. 8.
    Lundell I., Blomqvist A. G., Berglund M. M., Schober D. A., Johnson D., Statnick M. A., et al. (1995) Cloning of human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 270, 29,123–29,128.PubMedCrossRefGoogle Scholar
  9. 9.
    Weinberg D. H., Sirinathsinghji D. J., Tan C. P., Shiao L. L., Morin N., Rigby M. R., et al. (1996) Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. 271, 16,435–16,438.PubMedCrossRefGoogle Scholar
  10. 10.
    Hu Y., Bloomquist B. T., Cornfield L. J., DeCarr L. B., Flores Riveros J. R., Friedman L., et al. (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. 271, 26,315–26,319.PubMedCrossRefGoogle Scholar
  11. 11.
    Stanley B. G., Magdalin W., Seirafi A., Nguyen M. M. and Leibowitz S. F. (1992) Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide’s effect. Peptides 13, 581–587.PubMedCrossRefGoogle Scholar
  12. 12.
    Wyss P., Stricker-Krongrad A., Brunner L., Miller J., Crossthwaite A., Whitebread S., et al. (1998) The pharmacology of neuropeptide Y (NPY) receptor mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul. Pept. 75-76, 363–371.PubMedCrossRefGoogle Scholar
  13. 13.
    Gold L. H. (1996) Integration of molecular biological techniques and behavioural pharmacology. Behav. Pharmacol. 7, 589–615.PubMedGoogle Scholar
  14. 14.
    Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J. R., et al. (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA 90, 4665–4669.PubMedCrossRefGoogle Scholar
  15. 15.
    Wahlestedt C. (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15, 42–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Monia B. P., Johnston J. F., Geiger T., Muller M., and Fabbro D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675.PubMedCrossRefGoogle Scholar
  17. 17.
    Helene C. and Toulme J. J. (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochem. Biophys. Acta 1049, 99–125.PubMedGoogle Scholar
  18. 18.
    Morris M. and Lucion A. B. (1995) Antisense oligonucleotides in the study of neuroendocrine systems. J. Neuroendocrinol. 7, 493–500.PubMedCrossRefGoogle Scholar
  19. 19.
    Paxinos G. and Watson C. (1986) The Rat Brain Stereotaxic Coordinates. Academic, London.Google Scholar
  20. 20.
    Lesniak W., Schaefer C., Grueninger S., and Chiesi M. (1995) Effect of alpha adrenergic stimulation and carnitine palmitoyl transferase I inhibition on hyper-trophying adult rat cardiomyocytes in culture. Mol. Cell. Biochem. 142, 25–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Schaffhauser A. O., Sricker-Krongrad A., Brunner L., Cumin F., Gerald G., Whitebread& S., et al. (1997) Inhibition of food intake by neuropeptide Y5 antisense oligodeoxynucleotides. Diabetes 46, 1792–1798.PubMedCrossRefGoogle Scholar
  22. 22.
    Tang-Christensen M., Kristensen P., Stidsen C. E., and Brand C. L. (1998) Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding response to exogenous neuropeptide Y. J. Neuroendocrinol. 159, 307–312.Google Scholar
  23. 23.
    Criscione L., Rigollier P., Batzl-Hartmann C., Rüeger H., Stricker-Krongrad A., Wyss P., et al. (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 102, 2136–2145.PubMedCrossRefGoogle Scholar
  24. 24.
    Marsh D. J., Hollopeter G., Kafer K. E., and Palmiter R. D. (1998) Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nature Med. 4, 718–721.PubMedCrossRefGoogle Scholar
  25. 25.
    Dryden S., Pickavance L., Tidd D., and Williams G. (1998) The lack of specificity of neuropeptide Y (NPY) antisense administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus. J. Endocrinol. 157, 169–175.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Andrea O. Schaffhauser
    • 1
  • Alain Stricker-Krongrad
    • 2
  • Karl G. Hofbauer
    • 3
  1. 1.Lonza Ltd.BaselSwitzerland
  2. 2.Metabolic DiseasesMillennium PharmaceuticalsCambridge
  3. 3.Metabolic and Cardiovascular ResearchNovartis Pharma AGBaselSwitzerland

Personalised recommendations